# Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women

> **NCT03834571** · PHASE2 · WITHDRAWN · sponsor: **AIDS Malignancy Consortium**

## Conditions studied

- Cervical Adenocarcinoma
- Cervical Adenosquamous Carcinoma
- Cervical Squamous Cell Carcinoma, Not Otherwise Specified
- FIGO Stage IIB Cervix Carcinoma
- FIGO Stage III Cervix Carcinoma
- FIGO Stage IVA Cervix Carcinoma
- HIV Infection

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Paclitaxel
- **PROCEDURE:** Patient Monitoring
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT03834571
- **Lead sponsor:** AIDS Malignancy Consortium
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-05-31
- **Primary completion:** 2025-01
- **Final completion:** 2025-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Not approved by CTEP
- **Last updated:** 2022-06-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03834571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03834571, "Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03834571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*